Glioma Response to IDH Inhibition: Real-World Experience.
Where this comes from
- Record sourced from PubMed, PMID 37738033.
- Also identified by DOI 10.1158/1078-0432.CCR-23-2164 and PMC identifier 10840794.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment of IDH-mutated non-enhancing grade 2 and 3 diffuse gliomas with ivosidenib leads to reduction of tumor size when assessed via volumetric MRI. Isocitrate dehydrogenase inhibition has a therapeutic benefit in patients with these tumors. See related article by Kamson et al., p. 4863.
Medical subject headings
- Brain Neoplasms
- Glioma